You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study

Citation Tools

Article menu

Download PDFPDF

Treatments
Short report
Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Winthrop K, Vargas JI, Drescher E, et al
Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study
RMD Open 2022;8:e002110. doi: 10.1136/rmdopen-2021-002110